Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab and Sorafenib in Advanced HCC
NCT01264705Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Jan 2011
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bavituximab in hepatocellular carcinoma (HCC), sponsored by UT Southwestern Medical Center. Started Jan 2011; status: completed.
02
Drugs
bavituximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01264705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01264705.